文献速递介入腹部CT

经皮冷冻消融治疗血管周围性肝细胞癌:疗效与血管并发症

Percutaneous cryoablation for perivascular hepatocellular carcinoma: Therapeutic efficacy and vascular complications.
PubMed 文献 · Eur Radiol · 2018-07-24

研究纳入58例单发血管周围性肝细胞癌患者(2015年8月至2017年9月),行经皮冷冻消融,技术成功率96.6%(56/58),1年和2年累积局部肿瘤进展率分别为3.6%和14.6%,仅6.9%(4/58)出现瘤周血管血栓,无肝梗死及侵袭性瘤内复发,作者认为冷冻消融可能是治疗血管周围性肝细胞癌的有效手段且血管并发症风险很低。

要点

  • 冷冻消融治疗血管周围性肝细胞癌技术成功率96.6%(56/58)。
  • 1年和2年累积局部肿瘤进展率分别为3.6%和14.6%。
  • 瘤周血管血栓发生率6.9%(4/58),无肝梗死,未见侵袭性瘤内复发。

核心结论

  • 作者认为冷冻消融可能是治疗血管周围性肝细胞癌的有效手段,且血管并发症风险很低。

研究设计与样本

  • 单中心连续纳入2015年8月至2017年9月间58例接受经皮冷冻消融的患者(48男、10女,平均年龄61.1岁,年龄范围44-84岁),均为单发血管周围性肝细胞癌(平均大小1.3 cm,巴塞罗那临床肝癌分期0或A期),肿瘤与肝血管接触且血管轴位直径≥3 mm。
  • 局部肿瘤进展采用Kaplan-Meier法评估;治疗后立即及随访CT评估瘤周血管血栓、梗死和侵袭性瘤内复发(同时出现≥3个结节或浸润性肿瘤);所有患者术后1个月及之后每3个月行随访CT。

关键影像表现/征象

  • 随访CT显示瘤周血管血栓发生于6.9%(4/58)的病例,未见肝梗死,随访期间未出现侵袭性瘤内复发。
  • 冷冻消融后即刻出现的瘤周血管血栓中,一半在随访CT图像上消失。

诊断标准与关键数值

  • 技术成功率为96.6%(56/58)。
  • 中位随访22个月(范围3-29个月),1年和2年累积局部肿瘤进展率分别为3.6%和14.6%。
  • 瘤周血管血栓发生率为6.9%(4/58),肝梗死发生率为0,侵袭性瘤内复发发生率为0。

临床应用与阅片要点

  • 对血管周围性肝细胞癌行经皮冷冻消融时,可关注术后即刻及随访CT上瘤周血管血栓的出现,本研究中此类血栓未伴发肝梗死且部分可消失。
  • 随访CT方案为术后1个月及之后每3个月,用于监测局部肿瘤进展和侵袭性瘤内复发。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To evaluate the therapeutic efficacy of and vascular complications associated with percutaneous cryoablation for the treatment of perivascular HCC.

METHODS: Between August 2015 and September 2017, 58 consecutive patients (48 men, 10 women; mean age, 61.1 years; age range, 44-84 years) who underwent percutaneous cryoablation were included. All patients had a single perivascular HCC (mean size, 1.3 cm; Barcelona clinic liver cancer-stage 0 or A) that was in contact with hepatic vessels, ≥ 3 mm or larger in axial diameter. Local tumour progression (LTP) was estimated by the Kaplan-Meier method. In addition, several procedure-related vascular complications were evaluated immediately after treatment and during follow-up CT: peritumoral vessel thrombosis; infarction; aggressive intrasegmental recurrence (AIR) (the simultaneous development of ≥ 3 nodular or infiltrative tumours). The follow-up CT was performed in all patients 1 month after the procedure, and every 3 months thereafter.

RESULTS: The median follow-up period was 22 months (range, 3-29 months). The technical success rate of cryoablation was 96.6% (56/58). The 1- and 2-year cumulative LTP rates were 3.6% and 14.6%, respectively. Although peritumoral vessel thrombosis occurred in 6.9% of cases (4/58), no cases of hepatic infarction were observed and AIR did not develop during follow-up. Half of the thombi in the peritumoral vessels immediately after cryoablation disappeared on follow-up CT images.

CONCLUSION: Cryoablation could be an effective tool for the treatment of perivascular HCC with a very low risk of vascular complications.

KEY POINTS: • Cryoablation allowed a high technical success rate for perivascular HCC. • Only 6.9% developed peritumoral vessel thrombosis without major vascular complications like infarction. • Two-year cumulative LTP rate was 14.6%, without aggressive tumour recurrence on follow-up.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Kim R, Kang TW, Cha DI, et al. Percutaneous cryoablation for perivascular hepatocellular carcinoma: Therapeutic efficacy and vascular complications. Eur Radiol. 2018. PMID: 30043160. doi:10.1007/s00330-018-5617-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。